[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dengue-vaccines\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dengue-vaccines":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100575777","characterisation-of-dengue-vaccine-induced-specific-immunity-in-vaccinees-with-and-without-prior-exposure-to-flavivirus-infections-or-vaccination-100575777",false,"NCT06776692","Characterisation of Dengue Vaccine-induced Specific Immunity in Vaccinees With and Without Prior Exposure to Flavivirus Infections or Vaccination","Characterisation of Dengue Vaccine (Qdenga®, TAK-003)-Induced Humoral and Cellular Specific Immunity in Vaccinees With and Without Prior Exposure to Flavivirus Infections or Vaccination","VaQDENV","Inclusion Criteria:\n\n* Subjects of both sexes presenting to the DITM to receive the anti-DENV vaccine whether or not they have had a history of prior DENV or other flaviviruses infection or a history of prior vaccination against other flaviviruses. These data will be recorded in the study CRF.\n* Age \\>= 4 years.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Age \\\u003C 4 years.\n* Absence of signed informed consent.",true,"ALL","4 Years",{"count":21,"type":22},402,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn about the immunity induced by the Qdenga® vaccine in vaccinees.\n\nParticipants that will receive the Dengue vaccine as part of their routine before a travel will be asked to undergo a blood sample at the time of administration of the first dose (T0), 24-48 hours after the first dose (T1) of the vaccine, immediately before the second dose (T2 ) and one to two months after the second dose (T3). Possibly a further sample will be collected within 2 years.",[26],"Dengue Vaccines",[28,29],"Dengue","Vaccine","RECRUITING","2025-05-16",{"date":33,"type":34},"2025-05-18","ACTUAL",{"date":36,"type":34},"2024-07-10",{"date":38,"type":22},"2028-01",{"name":40,"class":41},"IRCCS Sacro Cuore Don Calabria di Negrar","OTHER"]